Advertisement
Advertisement


News

Efavirenz and Suicide Risk

August/September 2014

 < Prev  |  1  |  2 

Bear in Mind

The results of the ACTG analysis show that in four clinical trials where regimens were randomly assigned, exposure to efavirenz was linked to a two-fold increased risk of suicidal thoughts or behaviours. Furthermore, eight out of nine participants who completed suicide were taking efavirenz.

Factors associated with an increased risk of thoughts of suicide or suicidal behaviour included the following:

  • exposure to efavirenz
  • history of injecting street drugs
  • prior to entering the studies analysed, a recent history of using medicines for treating anxiety, depression, bipolar illness or psychosis

The findings from the ACTG analysis should not be entirely surprising. Initial studies with efavirenz suggested that about 0.7% of 1,008 participants taking this drug vs. 0.3% of 635 participants who took an efavirenz-free regimen reported thoughts of suicide.

Advertisement

The ACTG researchers found and reviewed publicly available data used by the U.S. Food and Drug Administration (FDA) when reviewing the emerging data from efavirenz in clinical trials many years ago. In these early clinical trials, there were cases of "serious nervous system or psychiatric experiences" that could include the following outcomes arising from exposure to efavirenz:

  • aggravated or severe depression
  • hallucinations
  • thoughts of suicide
  • attempted suicide
  • outbursts of anger
  • paranoia
  • mania


Other Studies

The overall level of suicidality found in the ACTG's analysis is similar to that seen in an earlier French study. Bear in mind that in either the ACTG or French study, it is possible that given the stigma surrounding mental health issues, including suicide, some participants may have chosen not to report such suicidality.

Suicidality occurred throughout the monitoring period of the ACTG's trials -- three years.


Strengths and Weaknesses

The analysis by the ACTG was done on four randomized clinical trials. The number of participants was large and diverse.

However, the ACTG's methods did have some relative weaknesses. Three of the four studies were not double blind; that is, participants and their doctors and nurses knew who was taking which regimens.

Another important weakness was that the trials were not originally designed to assess the potential for suicide. Bear in mind that clinical trials for HIV drugs are generally not designed for the purpose of assessing the potential of anti-HIV drugs for suicidality. Such trials would have to be very large (several thousand people) and run for many years and would therefore be very expensive. Furthermore, as safer, better tolerated and more potent regimens than efavirenz are available today, clinical trials exploring the adverse effects of efavirenz are unlikely to be launched in high-income countries.


Recommendations

Despite the previously mentioned weaknesses of the ACTG's reanalysis of clinical trial data, it is likely that there is a relationship between exposure to efavirenz and an increased risk for suicide in a relatively small number of people who use it. The U.S. researchers stated that the risk for suicidality that they found associated with efavirenz is "clinically relevant." They therefore encourage doctors and nurses treating HIV-positive patients who use efavirenz to do the following:

  • Such patients "should be monitored carefully for [signs or symptoms of worsening] depression or evidence of suicidal thoughts or behaviour."

Furthermore, the editors of the journal The Annals of Internal Medicine, in which the ACTG report was published, made this statement:

  • "An increased risk for suicidality should be considered when choosing efavirenz as part of an initial antiretroviral regimen."


References

  1. Scourfield A, Zheng J, Chinthapalli S, et al. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS. 2012 Jul 17;26(11):1399-401.
  2. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Annals of Internal Medicine. 2014 Jul 1;161(1):1-10.
  3. Raffi F, Pozniak AL, Wainberg MA. Has the time come to abandon efavirenz for first-line antiretroviral therapy? Journal of Antimicrobial Chemotherapy. 2014 Jul;69(7):1742-7.
  4. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011 Apr 19;76(16):1403-9.
  5. Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS. 2011 Jan 2;25(1):57-63.
  6. Waters L, Fisher M, Winston A, et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS. 2011 Jan 2;25(1):65-71.
 < Prev  |  1  |  2 



This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication TreatmentUpdate. Visit CATIE's Web site to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.